Global Healthcare Div A (MID325)
15.35
+0.04
(+0.27%)
CAD |
Mar 30 2023
Key Stats
| Expense Ratio | Total Assets Under Management | Dividend Yield | Turnover Ratio |
|---|---|---|---|
| 2.62% | 91.46M | 5.73% | 20.63% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized All Time Total Returns (Daily) | Max Drawdown (All) |
| -1.636M | 0.62% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The Fund’s objective is to provide holders of units with (i) stable quarterly cash distributions, and (ii) long-term total returns through distributions and capital appreciation of the Fund’s portfolio.The Fund’s investment strategy focuses on investing in dividend paying securities of global issuers that derive a significant portion of their revenue or earnings from products or services related to healthcare. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | MID325 |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | Sector Equity |
| Category Index | Morningstar Gbl GR CAD |
| Global Category Name | Equity Miscellaneous |
| YCharts Categorization | Other |
| YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
| Prospectus Objective | -- |
| Fund Owner Firm Name | Middlefield Limited |
| Prospectus Benchmark Index | |
| MSCI Daily World Healthcare NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Dean Orrico | 8.36 yrs |
| Robert Moffat | 1.96 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
47
-1.636M
-120.22M
Category Low
464.45M
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of February 28, 2023
Risk
Performance Versus Category
As of March 30, 2023. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of March 30, 2023.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| AstraZeneca PLC | 4.90% | 140.16 | 0.62% |
| Merck & Co Inc | 4.74% | 106.38 | 0.43% |
| AbbVie Inc | 4.58% | 159.35 | 0.91% |
| Thermo Fisher Scientific Inc | 4.44% | 576.22 | 2.35% |
| Eli Lilly and Co | 4.17% | 343.34 | 0.78% |
| McKesson Corp | 4.17% | 355.88 | -0.53% |
| UnitedHealth Group Inc | 3.90% | 472.42 | 0.50% |
| Johnson & Johnson | 3.88% | 154.72 | 0.84% |
| Danaher Corp | 3.87% | 251.94 | 0.85% |
| Pfizer Inc | 3.32% | 40.80 | 1.03% |
Basic Info
| Investment Strategy | |
| The Fund’s objective is to provide holders of units with (i) stable quarterly cash distributions, and (ii) long-term total returns through distributions and capital appreciation of the Fund’s portfolio.The Fund’s investment strategy focuses on investing in dividend paying securities of global issuers that derive a significant portion of their revenue or earnings from products or services related to healthcare. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | MID325 |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | Sector Equity |
| Category Index | Morningstar Gbl GR CAD |
| Global Category Name | Equity Miscellaneous |
| YCharts Categorization | Other |
| YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
| Prospectus Objective | -- |
| Fund Owner Firm Name | Middlefield Limited |
| Prospectus Benchmark Index | |
| MSCI Daily World Healthcare NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Dean Orrico | 8.36 yrs |
| Robert Moffat | 1.96 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (3-30-23) | 5.73% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield (2-28-23) | Upgrade |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 24.24 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of February 28, 2023
Fund Details
| Key Dates | |
| Inception Date | 10/23/2014 |
| Last Annual Report Date | 12/31/2018 |
| Last Prospectus Date | -- |
| Share Classes | |
| MID326 | Fee-based Advice |
| Attributes | |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |